This is a PDF file of a peer-reviewed paper that has been accepted for publication. Although unedited, the content has been subjected to preliminary formatting. Nature is providing this early version of the typeset paper as a service to our authors and readers. The text and figures will undergo copyediting and a proof review before the paper is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.
Background Substance use is a leading cause of morbidity and mortality that is under-identified in medical practice. Objective The Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS) Tool was developed to address the need for a brief screening and assessment instrument that includes all commonly used substances, and fits into clinical workflows. The goal of this study was to assess the performance of the TAPS Tool in primary care patients. Design Multi-site study conducted within the National Drug Abuse Treatment Clinical Trials Network, comparing the TAPS Tool against a reference standard measure. Setting Five adult primary care clinics. Participants 2,000 adult patients were consecutively recruited from clinic waiting areas. Measurements Interviewer- and self-administered versions of the TAPS Tool were compared to the reference standard modified Composite International Diagnostic Interview (CIDI), which measures problem use and substance use disorders (SUD). Results Interviewer- and self-administered versions of the TAPS Tool had similar diagnostic characteristics. For identifying problem use (at a cutoff of 1+), the TAPS Tool had sensitivity 0.93 (95% CI 0.90–0.95) and specificity 0.87 (95% CI 0.85–0.89) for tobacco, and sensitivity 0.74 (95% CI 0.70–0.78), specificity 0.79 (95% CI 0.76–0.81) for alcohol. For problem use of illicit and prescription drugs, sensitivity ranged from 0.82 (95% CI 0.76–0.87) for marijuana to 0.63 (95% CI 0.47–0.78) for sedatives, and specificity was 0.93 or higher. For identifying any SUD, sensitivity was lower, but a score of 2+ greatly increased the likelihood of having a SUD. Limitations Low prevalence of some drug classes led to poor precision in some estimates. Research assistants were not blinded to the participant’s TAPS Tool responses when they administered the CIDI. Conclusions In a diverse population of adult primary care patients, the TAPS Tool detected clinically relevant problem substance use. While it may also detect tobacco, alcohol, and marijuana use disorders, further refinement is needed before the TAPS Tool can be broadly recommended as a screener for SUD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.